Skip to main content
. Author manuscript; available in PMC: 2018 Mar 29.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2017 Mar;10(3):e001493. doi: 10.1161/CIRCOUTCOMES.115.001493

Table 4.

Discrimination Analysis of the Biomarker Risk Score With Major Cardiovascular Events

Model C Statistic (95% CI) ΔC Statistic (95% CI) Continuous NRI (95% CI) Relative IDI (95% CI)
All-cause death/MI
3-biomarker risk score 0.71 (0.67-0.75)
3-biomarker risk score+suPAR 0.74 (0.70-0.78) 0.03 (0.01-0.05) 0.60 (0.28-0.96) 0.10 (0.03-0.17)
All-cause death
3-biomarker risk score 0.71 (0.67-0.75)
3-biomarker risk score+suPAR 0.74 (0.70-0.78) 0.03 (0.01-0.06) 0.61 (0.27-0.99) 0.11 (0.03-0.19)
Cardiovascular death
3-biomarker risk score 0.71 (0.66-0.76)
3-biomarker risk score+suPAR 0.73 (0.68-0.79) 0.02 (0.00-0.05) 0.60 (0.13-0.86) 0.08 (0.01-0.16)
All-cause death/MI/revascularization
3-biomarker risk score 0.66 (0.63-0.69)
3-biomarker risk score+suPAR 0.67 (0.64-0.70) 0.01 (0.00-0.02) 0.57 (0.26-0.83) 0.05 (0.01-0.09)
All-cause death/MI/stroke
3-biomarker risk score 0.70 (0.66-0.75)
3-biomarker risk score+suPAR 0.73 (0.70-0.77) 0.03 (0.01-0.05) 0.60 (0.10-0.99) 0.10 (0.02-0.16)

Baseline model comprised age, sex, race, body mass index, a history of smoking, glomerular filtration rate, history of myocardial infarction, history of revascularization (coronary bypass graft or percutaneous coronary intervention), hypertension, dyslipidemia, diabetes mellitus, left ventricular ejection fraction, presence of obstructive coronary artery disease, aspirin use, statin use, and clopidogrel use. CI indicates confidence interval; IDI, integrated discrimination improvement; MI, myocardial infarction; NRI, net reclassification index; and suPAR, soluble urokinase plasminogen activator receptor.